Not provided
Not provided
Not provided
Not provided
Not provided
The decision to terminate was completely related to efficacy and there were no safety concerns.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This initial proof of concept, phase II study aims to assess the safety and efficacy of UK-500,001 for the chronic maintenance treatment of adults with Chronic Obstructive Pulmonary Disease.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| UK-500,001 | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in forced expiratory volume in 1 second (FEV1) compared to placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in other lung function parameters, dyspnea, quality of life compared to placebo |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | La Plata | Buenos Aires | C1904AGP | Argentina | ||
| Pfizer Investigational Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 19213793 | Derived | Vestbo J, Tan L, Atkinson G, Ward J; UK-500,001 Global Study Team. A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Respir J. 2009 May;33(5):1039-44. doi: 10.1183/09031936.00068908. Epub 2009 Feb 12. |
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Vicente López |
| Buenos Aires |
| 1602 |
| Argentina |
| Pfizer Investigational Site | Rosario | Santa Fé | 2000 | Argentina |
| Pfizer Investigational Site | Buenos Aires | 1426 | Argentina |
| Pfizer Investigational Site | Buenos Aires | C1425DQU | Argentina |
| Pfizer Investigational Site | Camperdown | New South Wales | 2050 | Australia |
| Pfizer Investigational Site | Clayton | Victoria | 3168a | Australia |
| Pfizer Investigational Site | Nedlands | Western Australia | 6009 | Australia |
| Pfizer Investigational Site | Calgary | Alberta | T1Y 6J4 | Canada |
| Pfizer Investigational Site | Red Deer | Alberta | T4N 6V7 | Canada |
| Pfizer Investigational Site | Hamilton | Ontario | L8N 3Z5 | Canada |
| Pfizer Investigational Site | Kingston | Ontario | K7L 2V7 | Canada |
| Pfizer Investigational Site | Santiago | RM | 7500691 | Chile |
| Pfizer Investigational Site | Providencia | Santiago Metropolitan | 7500691 | Chile |
| Pfizer Investigational Site | ValparaÃ-so | ValparaÃ-so | 2381594 | Chile |
| Pfizer Investigational Site | Zagreb | 10000 | Croatia |
| Pfizer Investigational Site | Olomouc | 775 20 | Czechia |
| Pfizer Investigational Site | Ostrava-Poruba | 708 52 | Czechia |
| Pfizer Investigational Site | Prague | 150 06 | Czechia |
| Pfizer Investigational Site | Tábor | 390 03 | Czechia |
| Pfizer Investigational Site | Debrecen | 4004 | Hungary |
| Pfizer Investigational Site | Törökbálint | 2045 | Hungary |
| Pfizer Investigational Site | Veszprém | 8200 | Hungary |
| Pfizer Investigational Site | Singapore | 308433 | Singapore |
| Pfizer Investigational Site | Singapore | 529889 | Singapore |
| Pfizer Investigational Site | Madrid | Madrid | 28007 | Spain |
| Pfizer Investigational Site | Madrid | Madrid | 28046 | Spain |
| Pfizer Investigational Site | Manchester | M23 9LT | United Kingdom |
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided